TCA
FBRX icon

Transcend Capital Advisors’s Forte Biosciences FBRX Stock Holding History

Transcend Capital Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-320
Closed -$274K – 349
2021
Q1 		$274K Buy
+320
New +$262K 0.03% 327

Other funds holding FBRX

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Transcend Capital Advisors's FBRX Position: Q2 2021 in Review

Transcend Capital Advisors sold out of Forte Biosciences (FBRX) in Q2 2021, closing a stake of 320 shares — an estimated $274K sold.

Transcend Capital Advisors first reported a position in FBRX in Q1 2021 and held it in 1 quarter. The position peaked at $274K in Q1 2021. 75 funds tracked by Wall St. Rank hold FBRX as of Q2 2021.

  • Transcend Capital Advisors reported no remaining Forte Biosciences position as of Q2 2021 after selling out during the quarter.
  • Transcend Capital Advisors sold 320 Forte Biosciences shares in Q2 2021, an estimated $274K.
  • Transcend Capital Advisors first reported a position in Forte Biosciences in Q1 2021 and held it in 1 quarter.
  • Transcend Capital Advisors's Forte Biosciences position peaked at $274K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2021.

Based on Transcend Capital Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.